e-learning
resources
Virtual 2021
05.09.2021
News in treatment and diagnosis of idiopathic interstitial pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
J. Barnes (Cambridge, United Kingdom), E. Harris (Cambridge, United Kingdom), L. Matos (Cambridge, United Kingdom), K. Harding (Cambridge, United Kingdom), M. Thillai (Cambridge, United Kingdom)
Source:
Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Session:
News in treatment and diagnosis of idiopathic interstitial pneumonia
Session type:
E-poster
Number:
467
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Barnes (Cambridge, United Kingdom), E. Harris (Cambridge, United Kingdom), L. Matos (Cambridge, United Kingdom), K. Harding (Cambridge, United Kingdom), M. Thillai (Cambridge, United Kingdom). Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study. 467
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
emily faye - 31.03.2024 03:19
I have been suffering from Herpes for the past 1 years and 8 months, and ever since then I have been taking series of treatment but there was no improvement until I came across testimonies of Dr. Silver on how he has been curing different people from different diseases all over the world, then I contacted him as well. After our conversation he sent me the medicine which I took according .to his instructions. When I was done taking the herbal medicine I went for a medical checkup and to my greatest surprise I was cured from Herpes. My heart is so filled with joy. If you are suffering from Herpes or any other disease you can contact Dr. Silver today on this Email address: drsilverhealingtemple@gmail.com or Whatsapp +2348120513902
BEN KALS - 05.12.2023 16:58
I am so glad writing this article today to tell the world how i was cured from HSV VIRUS, I was diagnosed with HSV-1&2 for three years before Dr Timothy cured me with his herbal roots and herbs precaution which he sent to me through DHL delivery service...( a herbal drink and a tree root branch) if you are going through same situation you can contact him on his website https://5dc41d5b6d60d.site123.me or email goodhealthherbalfoundation1@gmail.com herpes is such a nasty virus.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020
Year: 2021
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Exacerbations, hospitalisations and mortality in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems
Year: 2017
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries.
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018
Year: 2019
Effect of delayed secondary care referral on morbidity and mortality in idiopathic pulmonary fibrosis patients treated with antifibrotics
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Source: Breathe, 15 (2) 144; 10.1183/20734735.0016-2019
Year: 2019
A registry of patients with idiopathic pulmonary fibrosis in Russia: 2-yr results and therapeutic modalities in real-life practice
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019
Year: 2020
Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept